Posted by Michael Wonder on 14 Feb 2022
Avion Pharmaceuticals, an Alora Pharmaceuticals company, announces the FDA approval and availability of Dhivy for the treatment of Parkinson's disease
14 February 2022 - Parkinson's disease treatment is the first and only carbidopa/levodopa tablet designed to be divided for precise dosing.
Avion Pharmaceuticals announced the commercial launch of Dhivy, the first and only carbidopa/levodopa fractional tablet designed to be divided. Avion gained approval for Dhivy from the FDA in November 2021.
This unique design enables more precise medication dosing and directly addresses a market need to assist in titration for the gold standard commonly used by those with Parkinson's disease, the fastest-growing neurological condition in the United States, for which there is currently no cure.
